New Dengue Vaccine Could Protect People From Disease If Targeted Accurately

Thomson Reuters Foundation: Dengue vaccine no silver bullet but worth a shot for those who need it most
Stefan Flasche, assistant professor at the London School of Hygiene & Tropical Medicine’s department of infectious disease epidemiology

“…A new London School of Hygiene & Tropical Medicine-led study published in the journal PLOS Medicine, initiated by the World Health Organization, and conducted with a team of international experts … showed that giving [the CYD-TDV dengue vaccine] only to those populations with a high burden of disease has the potential to prevent about one out of five dengue hospitalizations. It predicts that a substantial positive impact of vaccination can be achieved if targeted at individuals who most likely had an infection before and, if priced competitively, a cost-effectiveness profile that is similar to that of other vaccines currently in use. … The global health community must ensure that we are in a position to make best use of this dengue vaccine until other, more effective means of prevention become available. CYD-TDV is no silver bullet, but if targeted accurately it will bring help to those who need it most” (11/29).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

The Henry J. Kaiser Family Foundation Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270

www.kff.org | Email Alerts: kff.org/email | facebook.com/KaiserFamilyFoundation | twitter.com/kff

Filling the need for trusted information on national health issues, the Kaiser Family Foundation is a nonprofit organization based in San Francisco, California.